tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

AAgilent Technologies

Health care · Lab Instruments · NYSE
A quote by TradingView
Employees
18,100
Headquarters
Santa Clara, CA
CEO
Padraig McDonnell
Next results
around Nov 23, 2026
Compare with peers → Embed
All key numbers (42, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)5.07Sales (ttm)7.4BNet income (ttm)1.4BSales growth+6.7%EPS growth+3.2%Sales Q/Q+8.1%
Free cash flow1.3BGross margin53.8%Oper. margin22.2%Net margin19.5%FCF margin17.2%ROE19.6%
ROA10.3%R&D / sales6.5%Dividend0.99Debt/Eq0.54Curr. ratio2.05Cash1.8B
Op. cash flow (ttm)1.6BEBITDA1.8BEBITDA margin25.4%Net debt2.2BQuick ratio1.60Interest cover13.21
ROIC11.9%Payout ratio21.7%Tax rate9.2%Stock pay / sales1.8%Shares out.281.9MShares Y/Y-2.1%
Book / share26.12Cash / share6.24Sales / share26.15Asset turnover0.53Inventory turns3.22Days sales out.78
Sales 3Y CAGR+0.5%Sales 5Y CAGR+5.4%EPS 3Y CAGR+3.0%EPS 5Y CAGR+14.7%Employees18,100Sales / employee407K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2025 against FY2024
  • Revenue growth sped up to +6.7%-4.7% → +6.7% · Revenue FY2025 / revenue FY2024 − 1, against the same a year earlier · 10-K ↗
What management wrote about it → · Every company →

A against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
APeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+6.7%33rd of 60 · median +7.1%
Net margin
19.5%12th of 60 · median 9.6%
Return on equity
19.6%14th of 54 · median 13.1%
Free cash flow margin
17.2%24th of 56 · median 15.5%
Debt / equity (less is better)
0.5416th of 49 · median 0.66
A and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
A Agilent Technologies$7.4B +6.7%53.8%19.5%19.6%17.2%0.54
ZBH Zimmer Biomet$8.6B +7.2%69.7%9.0%6.0%19.2%0.59
SOLV Solventum$8.2B +0.9%54.8%1.9%3.2%0.0%0.95
EW Edwards Lifesciences$6.7B +11.5%78.0%15.3%9.4%21.3%0.06
STE Steris$6.2B +8.7%44.6%13.4%11.4%15.2%0.26
INCY Incyte$6.0B +21.2%92.7%6.7%7.1%--

From $6.3B of sales to $1.2B of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $3.4BRevenue to Cost of revenue: $2.9BGross profit to Operating profit: $1.3BGross profit to Operating expenses: $2.1BOperating profit to Net profit: $1.2BOperating profit to Tax & other: $137.0MOperating expenses to R&D: $441.0MOperating expenses to SG&A: $1.6B Revenue: $6.3B Revenue$6.3B +18% Y/Y Gross profit: $3.4B · 54% margin Gross profit$3.4B54% margin Cost of revenue: $2.9B · 46% of revenue Cost of revenue$2.9B46% of revenue Operating profit: $1.3B · 21% margin Operating profit$1.3B21% margin +59% Y/Y Operating expenses: $2.1B · 33% of revenue Operating expenses$2.1B33% of revenue Net profit: $1.2B · 19% margin Net profit$1.2B19% margin +68% Y/Y Tax & other: $137.0M · 2% of revenue Tax & other$137.0M2% of revenue R&D: $441.0M · 7% of revenue R&D$441.0M7% of revenue SG&A: $1.6B · 26% of revenue SG&A$1.6B26% of revenue

Swipe sideways for the whole flow →

From $6.8B of sales to $1.3B of profit

FY2022, from the 10-K income statement and revenue by segment
Agilent CrossLab to Revenue: $1.5BLife Sciences and Applied Markets to Revenue: $3.6BDiagnostics and Genomics to Revenue: $1.8BRevenue to Gross profit: $3.7BRevenue to Cost of revenue: $3.1BGross profit to Operating profit: $1.6BGross profit to Operating expenses: $2.1BOperating profit to Net profit: $1.3BOperating profit to Tax & other: $364.0MOperating expenses to R&D: $467.0MOperating expenses to SG&A: $1.6B Agilent CrossLab: $1.5B · 21% Agilent CrossLab$1.5B21% Life Sciences and Applied Markets: $3.6B · 53% Life Sciences and Appli…$3.6B53% Diagnostics and Genomics: $1.8B · 26% Diagnostics and Genomics$1.8B26% Revenue: $6.8B Revenue$6.8B +8% Y/Y Gross profit: $3.7B · 54% margin Gross profit$3.7B54% margin Cost of revenue: $3.1B · 46% of revenue Cost of revenue$3.1B46% of revenue Operating profit: $1.6B · 24% margin Operating profit$1.6B24% margin +20% Y/Y Operating expenses: $2.1B · 31% of revenue Operating expenses$2.1B31% of revenue Net profit: $1.3B · 18% margin Net profit$1.3B18% margin +4% Y/Y Tax & other: $364.0M · 5% of revenue Tax & other$364.0M5% of revenue R&D: $467.0M · 7% of revenue R&D$467.0M7% of revenue SG&A: $1.6B · 24% of revenue SG&A$1.6B24% of revenue

Swipe sideways for the whole flow →

From $6.8B of sales to $1.2B of profit

FY2023, from the 10-K income statement
Revenue to Gross profit: $3.5BRevenue to Cost of revenue: $3.4BGross profit to Operating profit: $1.4BGross profit to Operating expenses: $2.1BOperating profit to Net profit: $1.2BOperating profit to Tax & other: $110.0MOperating expenses to R&D: $481.0MOperating expenses to SG&A: $1.6B Revenue: $6.8B Revenue$6.8B +0% Y/Y Gross profit: $3.5B · 51% margin Gross profit$3.5B51% margin Cost of revenue: $3.4B · 49% of revenue Cost of revenue$3.4B49% of revenue Operating profit: $1.4B · 20% margin Operating profit$1.4B20% margin −17% Y/Y Operating expenses: $2.1B · 31% of revenue Operating expenses$2.1B31% of revenue Net profit: $1.2B · 18% margin Net profit$1.2B18% margin −1% Y/Y Tax & other: $110.0M · 2% of revenue Tax & other$110.0M2% of revenue R&D: $481.0M · 7% of revenue R&D$481.0M7% of revenue SG&A: $1.6B · 24% of revenue SG&A$1.6B24% of revenue

Swipe sideways for the whole flow →

From $6.5B of sales to $1.3B of profit

FY2024, from the 10-K income statement
Revenue to Gross profit: $3.5BRevenue to Cost of revenue: $3.0BGross profit to Operating profit: $1.5BGross profit to Operating expenses: $2.0BOperating profit to Net profit: $1.3BOperating profit to Tax & other: $199.0MOperating expenses to R&D: $479.0MOperating expenses to SG&A: $1.6B Revenue: $6.5B Revenue$6.5B −5% Y/Y Gross profit: $3.5B · 54% margin Gross profit$3.5B54% margin Cost of revenue: $3.0B · 46% of revenue Cost of revenue$3.0B46% of revenue Operating profit: $1.5B · 23% margin Operating profit$1.5B23% margin +10% Y/Y Operating expenses: $2.0B · 31% of revenue Operating expenses$2.0B31% of revenue Net profit: $1.3B · 20% margin Net profit$1.3B20% margin +4% Y/Y Tax & other: $199.0M · 3% of revenue Tax & other$199.0M3% of revenue R&D: $479.0M · 7% of revenue R&D$479.0M7% of revenue SG&A: $1.6B · 24% of revenue SG&A$1.6B24% of revenue

Swipe sideways for the whole flow →

From $6.9B of sales to $1.3B of profit

FY2025, from the 10-K income statement and revenue by segment
Agilent CrossLab to Revenue: $2.9BLife Sciences and Diagnostics Markets to Revenue: $2.7BApplied Markets to Revenue: $1.3BRevenue to Gross profit: $3.6BRevenue to Cost of revenue: $3.3BGross profit to Operating profit: $1.5BGross profit to Operating expenses: $2.2BOperating profit to Net profit: $1.3BOperating profit to Tax & other: $176.0MOperating expenses to R&D: $455.0MOperating expenses to SG&A: $1.7B Agilent CrossLab: $2.9B · 42% Agilent CrossLab$2.9B42% Life Sciences and Diagnostics Markets: $2.7B · 39% Life Sciences and Diagn…$2.7B39% Applied Markets: $1.3B · 19% Applied Markets$1.3B19% Revenue: $6.9B Revenue$6.9B +7% Y/Y Gross profit: $3.6B · 52% margin Gross profit$3.6B52% margin Cost of revenue: $3.3B · 48% of revenue Cost of revenue$3.3B48% of revenue Operating profit: $1.5B · 21% margin Operating profit$1.5B21% margin −1% Y/Y Operating expenses: $2.2B · 31% of revenue Operating expenses$2.2B31% of revenue Net profit: $1.3B · 19% margin Net profit$1.3B19% margin +1% Y/Y Tax & other: $176.0M · 3% of revenue Tax & other$176.0M3% of revenue R&D: $455.0M · 7% of revenue R&D$455.0M7% of revenue SG&A: $1.7B · 25% of revenue SG&A$1.7B25% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

3 of 3
  • ✓
    Net margin above the peer median19.5% vs 9.6%
  • ✓
    Return on equity above 15%19.6%
  • ✓
    A profit in every one of 10 years
Net margin, FY2016 to FY2025: 11.0% → 18.8%

Balance sheet

4 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 13.2× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.54 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 2.05
  • ✓
    Net debt under 3 years of free cash flow$2.2B net debt, 1.7 years
Debt / equity at each year end, FY2016 to FY2025: 0.44 → 0.50
What the debt is made of ↓

Cash and shareholders

4 of 4
  • ✓
    Free cash flow positive in every one of 10 years$1.2B last year
  • ✓
    Share count down over 5 years−8.7%
  • ✓
    Dividend per share up over 5 years$0.72 → $0.99
  • ✓
    Cash from operations above net income$1.6B vs $1.3B
Free cash flow, FY2016 to FY2025: 654.0M → 1.2B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

What the debt is made of, and when it is due

balance sheet of Jul 31, 2026
Debt: $3.9B Debt$3.9B Long-term debt: $3.6B · 92% Long-term debt$3.6B · 92% Short-term borrowings: $304.0M · 8% Short-term borrowings$304.0M · 8%

The debt note's own lines, 2025-10-31

Line, as the company names itKindRateFixed or floatingAmount
Senior NotesTotal of the lines–not stated$3.0B
Senior Notes 2031 (Senior Notes)Notes and bonds–not stated$845.0M
Senior Notes 2027 (Senior Notes)Notes and bonds–not stated$597.0M
Senior Notes 2034 (Senior Notes)Notes and bonds–not stated$593.0M
Senior Notes 2030 (Senior Notes)Notes and bonds–not stated$498.0M
Senior Notes 2029 (Senior Notes)Notes and bonds–not stated$497.0M
Other Loans––not stated$20.0M

From the debt note in the 10-K's XBRL (0001090872-25-000087), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.

Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →

Revenue and net income, FY2016 to FY2025

Revenue 6.9B Net income 1.3B
FY2016 revenue 4.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-18-000019 FY2016 net income 462.0M · ProfitLoss, 0001090872-18-000019 4.2B FY2016 FY2017 revenue 4.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-19-000022 FY2017 net income 684.0M · ProfitLoss, 0001090872-19-000022 4.5B FY2017 FY2018 revenue 4.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-20-000020 FY2018 net income 316.0M · ProfitLoss, 0001090872-20-000020 4.9B FY2018 FY2019 revenue 5.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-21-000027 FY2019 net income 1.1B · ProfitLoss, 0001090872-21-000027 5.2B FY2019 FY2020 revenue 5.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-22-000026 FY2020 net income 719.0M · NetIncomeLoss, 0001090872-22-000026 5.3B FY2020 FY2021 revenue 6.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-23-000020 FY2021 net income 1.2B · NetIncomeLoss, 0001090872-23-000020 6.3B FY2021 FY2022 revenue 6.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-24-000049 FY2022 net income 1.3B · NetIncomeLoss, 0001090872-24-000049 6.8B FY2022 FY2023 revenue 6.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-25-000087 FY2023 net income 1.2B · NetIncomeLoss, 0001090872-25-000087 6.8B FY2023 FY2024 revenue 6.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-25-000087 FY2024 net income 1.3B · NetIncomeLoss, 0001090872-25-000087 6.5B FY2024 FY2025 revenue 6.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001090872-25-000087 FY2025 net income 1.3B · NetIncomeLoss, 0001090872-25-000087 6.9B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

A's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue6.9B
FY2016: 4.2BFY2017: 4.5BFY2018: 4.9BFY2019: 5.2BFY2020: 5.3BFY2021: 6.3BFY2022: 6.8BFY2023: 6.8BFY2024: 6.5BFY2025: 6.9B FY2017FY2019FY2021FY2023FY2025
Net income1.3B
FY2016: 462.0MFY2017: 684.0MFY2018: 316.0MFY2019: 1.1BFY2020: 719.0MFY2021: 1.2BFY2022: 1.3BFY2023: 1.2BFY2024: 1.3BFY2025: 1.3B FY2017FY2019FY2021FY2023FY2025
Free cash flow1.2B
FY2016: 654.0MFY2017: 713.0MFY2018: 910.0MFY2019: 866.0MFY2020: 802.0MFY2021: 1.3BFY2022: 1.0BFY2023: 1.5BFY2024: 1.4BFY2025: 1.2B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)4.57
FY2016: 1.40FY2017: 2.10FY2018: 0.97FY2019: 3.37FY2020: 2.30FY2021: 3.94FY2022: 4.18FY2023: 4.19FY2024: 4.43FY2025: 4.57 FY2017FY2019FY2021FY2023FY2025
Dividend per share0.99
FY2016: 0.46FY2017: 0.53FY2018: 0.60FY2019: 0.66FY2020: 0.72FY2021: 0.78FY2022: 0.84FY2023: 0.90FY2024: 0.94FY2025: 0.99 FY2017FY2019FY2021FY2023FY2025
Diluted shares285.0M
FY2016: 329.0MFY2017: 326.0MFY2018: 325.0MFY2019: 318.0MFY2020: 312.0MFY2021: 307.0MFY2022: 300.0MFY2023: 296.0MFY2024: 291.0MFY2025: 285.0M FY2017FY2019FY2021FY2023FY2025

The segments changed

10-K filed 2025-12-22

Compared with the 10-K of Dec 20, 2024: new segments Applied Markets, Life Sciences and Diagnostics Markets; no longer reported: Diagnostics and Genomics, Life Sciences and Applied Markets.

In the first quarter of fiscal year 2025, we reorganized our operating segments; see Note 22, "Segment Information" for additional information about our segment reorganization. 10-K

When a company changes its segments, the years before are usually recast, so growth by segment is not comparable with what earlier 10-Ks showed. Found by comparing the segments with revenue in the last two 10-Ks (XBRL) and by the 10-K's own words, without AI.

Revenue by business segment

year to Oct 31, 2025
RevenueSharevs year before
Agilent CrossLab 2.9B41.9% +5.9%
Life Sciences and Diagnostics Markets 2.7B39.2% +10.5%
Applied Markets 1.3B18.9% +1.3%

10-K 0001090872-25-000087, segment and revenue notes (XBRL).

Revenue by product or service

year to Oct 31, 2025
RevenueSharevs year before
Non-Instrumentation and Other 4.5B65.1% +8.8%
Instrumentation 2.4B34.9% +3.1%

10-K 0001090872-25-000087, segment and revenue notes (XBRL).

Revenue by region

year to Oct 31, 2025
RevenueSharevs year before
Rest Of World 3.4B48.7% +11.0%
Americas 2.8B40.4% +9.1%
UNITED STATES 2.3B33.7% +4.3%
Asia Pacific 2.2B31.9% +2.4%
Europe 1.9B27.7% +8.6%
CHINA Including Hong Kong 1.2B17.6% +0.6%

10-K 0001090872-25-000087, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue4.2B4.5B4.9B5.2B5.3B6.3B6.8B6.8B6.5B6.9B
Cost of revenue2.0B2.1B2.2B2.4B2.5B2.9B3.1B3.4B3.0B3.3B
R&D329.0M341.0M387.0M404.0M495.0M441.0M467.0M481.0M479.0M455.0M
SG&A1.3B1.3B1.4B1.5B1.5B1.6B1.6B1.6B1.6B1.7B
Operating income615.0M807.0M904.0M941.0M846.0M1.3B1.6B1.4B1.5B1.5B
Interest expense72.0M79.0M75.0M74.0M78.0M81.0M84.0M95.0M96.0M112.0M
Pretax income859.0M974.0M946.0M919.0M842.0M1.4B1.5B1.3B1.5B1.4B
Income tax82.0M119.0M630.0M-152.0M123.0M150.0M250.0M99.0M232.0M132.0M
Net income462.0M684.0M316.0M1.1B719.0M1.2B1.3B1.2B1.3B1.3B
EPS (diluted)1.402.100.973.372.303.944.184.194.434.57
Diluted shares329.0M326.0M325.0M318.0M312.0M307.0M300.0M296.0M291.0M285.0M
Depreciation & amortization246.0M212.0M210.0M238.0M308.0M321.0M317.0M271.0M257.0M288.0M
EBITDA861.0M1.0B1.1B1.2B1.2B1.7B1.9B1.6B1.7B1.8B
Operating margin14.6%18.0%18.4%18.2%15.8%21.3%23.6%19.8%22.9%21.3%
Net margin11.0%15.3%6.4%20.7%13.5%19.1%18.3%18.1%19.8%18.8%
Revenue growth-+6.4%+9.9%+5.1%+3.4%+18.4%+8.4%-0.2%-4.7%+6.7%
EPS growth-+50.0%-53.8%+247%-31.8%+71.3%+6.1%+0.2%+5.7%+3.2%

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash2.3B2.7B2.2B1.4B1.4B1.5B1.1B1.6B1.3B1.8B
Receivables631.0M724.0M776.0M930.0M1.0B1.2B1.4B1.3B1.3B1.5B
Inventory533.0M575.0M638.0M679.0M720.0M830.0M1.0B1.0B972.0M1.0B
Current assets3.6B4.2B3.8B3.2B3.4B3.8B3.8B4.2B4.0B4.6B
Property & equipment639.0M757.0M822.0M850.0M845.0M945.0M1.1B1.3B1.8B2.0B
Goodwill2.5B2.6B3.0B3.6B3.6B4.0B4.0B4.0B4.5B4.5B
Total assets7.8B8.4B8.5B9.5B9.6B10.7B10.5B10.8B11.8B12.7B
Accounts payable257.0M305.0M340.0M354.0M354.0M446.0M580.0M418.0M540.0M570.0M
Current liabilities945.0M1.3B1.2B2.1B1.5B1.7B1.9B1.6B1.9B2.3B
Total debt1.9B2.0B1.8B2.4B2.4B2.7B2.8B2.7B3.4B3.4B
Total liabilities3.5B3.6B4.0B4.7B4.8B5.3B5.2B4.9B5.9B6.0B
Shareholders' equity4.2B4.8B4.6B4.7B4.9B5.4B5.3B5.8B5.9B6.7B
Retained earnings6.1B-126.0M-336.0M-18.0M81.0M348.0M324.0M782.0M750.0M1.4B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow793.0M889.0M1.1B1.0B921.0M1.5B1.3B1.8B1.8B1.6B
Capital spending139.0M176.0M177.0M155.0M119.0M188.0M291.0M298.0M378.0M407.0M
Free cash flow654.0M713.0M910.0M866.0M802.0M1.3B1.0B1.5B1.4B1.2B
Stock-based pay (added back)58.0M60.0M70.0M72.0M83.0M110.0M125.0M111.0M129.0M128.0M
Dividends paid150.0M170.0M191.0M206.0M222.0M236.0M250.0M265.0M274.0M282.0M
Buybacks434.0M194.0M422.0M723.0M469.0M788.0M1.1B575.0M1.1B425.0M
Acquisitions261.0M128.0M516.0M1.4B0547.0M52.0M51.0M862.0M-4.0M
Debt raised299.0M00497.0M499.0M848.0M600.0M01.2B4.0M
Debt repaid0----417.0M609.0M0600.0M3.0M
Investing cash flow-238.0M-304.0M-705.0M-1.6B-147.0M-749.0M-338.0M-310.0M-1.3B-394.0M
Financing cash flow-268.0M-202.0M-797.0M-299.0M-717.0M-696.0M-1.4B-930.0M-752.0M-715.0M
Dividend per share0.460.530.600.660.720.780.840.900.940.99

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)58.0M60.0M70.0M72.0M83.0M110.0M125.0M111.0M129.0M128.0M
Stock-based pay / revenue1.4%1.3%1.4%1.4%1.6%1.7%1.8%1.6%2.0%1.8%
Operating lease cost----60.0M59.0M59.0M68.0M58.0M55.0M
Finance lease principal paid--004.0M00---
Right-of-use assets---0175.0M178.0M150.0M154.0M177.0M183.0M
Operating lease liabilities----178.0M182.0M152.0M164.0M184.0M189.0M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Work on A in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/A/export.csv") into a cell.